

Short Name	Comments	Type	Investigator	Contact
<b>Acute Kidney Disease</b>				
<b>Gambro HF-20</b>	<p><b>Clinical Evaluation of the Prismaflex HF20 Set and Prismaflex® System 7.10 for Acute Continuous Renal Replacement Therapy (CRRT) in Children</b></p> <p><i>This research study involves children who are admitted to the PICU and require Continuous Renal Replacement Therapy (CRRT) for treatment of an acute kidney injury. The purpose of the research is to evaluate the performance of the Gambro Prismaflex HF20 Set (a dialysis filter designed for small children) and the Prismaflex System 7.10 (the continuous dialysis machine) in delivering CRRT, in patients weighing between 8 kg (17.6 pounds) and 20 kg (44.09 pounds).</i></p> <p><a href="#">For More Information</a></p>	Treatment	<a href="#">Hackbarth, Richard</a>	Emily Gleason <a href="mailto:Emily.Gleason@helendevoschildrens.org">Emily.Gleason@helendevoschildrens.org</a> (616) 486-6332
<b>Chronic Kidney Disease</b>				
<b>CKiD</b>	<p><b>Chronic Kidney Disease in Children Prospective Cohort Study</b></p> <p><i>Chronic Kidney Disease in Children Prospective Cohort Study (CKiD), two cohorts of patients (20;10) opening an amendment, committing to enrolling three cohorts of 10 more over next three years. We are one of 52 sites, E coast region led by CHOP. Third cohort open. Children need to be under five years of age.</i></p> <p><a href="#">For More Information</a></p>	Registry	<a href="#">Quiroga Chand, Alejandro</a>	Pam McKee <a href="mailto:pamela.mckee@helendevoschildrens.org">pamela.mckee@helendevoschildrens.org</a> (616) 391-8534

<b>NAPRTCS Registry</b>	<b>NAPRTCS Registry</b>	Registry	<a href="#">Steinke, Julia</a>	Yvonne Edgerly <a href="mailto:Yvonne.Edgerly@spectrumhealth.org">Yvonne.Edgerly@spectrumhealth.org</a> (616) 391-5066
<i>The purpose of the registry is to enter scientific data on the care and treatment of pediatric kidney disease and transplantation into a national registry. Collecting this data into one nationwide registry is expected to improve medical care of children including those who have received renal transplants.</i>				

<b>Genome</b>	<b>Genome Wide Association Study of Childhood Onset Idiopathic Nephrotic Syndrome</b>	Registry	<a href="#">Cai, Yi</a>	Emily Beltz <a href="mailto:Emily.Beltz@spectrumhealth.org">Emily.Beltz@spectrumhealth.org</a> (616) 486-4936
<i>To investigate the genetic risk factors for idiopathic nephrotic syndrome (NS) and define common disease loci for childhood NS.</i>				

### **Lupus Nephritis**

<b>MWPNC Lupus Nephritis Registry</b>	<b>Pediatric Lupus Nephritis Registry</b>	Registry	<a href="#">Quiroga Chand, Alejandro</a>	Emily Beltz <a href="mailto:Emily.Beltz@spectrumhealth.org">Emily.Beltz@spectrumhealth.org</a> (616) 486-4936
---------------------------------------	---	----------	--	---

Systemic Lupus Erythematosus (SLE) is a chronic disease that affects more than a million people in the USA. Studies show that up to 80 percent of children with SLE disease will develop lupus nephritis. The registry plans to initially study if certain laboratory results predict outcomes and if there are differences in treatment outcomes between people of different races. This registry is being done by a group of pediatric nephrologists (kidney doctors for children) and rheumatologists (doctors who specialize in autoimmune diseases) throughout the United States who have joined efforts to study this disease.

---

**Nephrotic Syndrome**


---

<b>MWNPC Neph Syndrome Registry (CNOS)</b>	<b>Childhood Nephrotic Syndrome Observational Study</b>	Registry	<a href="#">Quiroga Chand, Alejandro</a>	Bill Boshoven <a href="mailto:William.Boshoven@spectrumhealth.org">William.Boshoven@spectrumhealth.org</a> (616) 486-6121
--	---	----------	--	---

*A registry of patients who have nephrotic syndrome. To gather information about how nephrotic syndrome progresses in different people and how or why that happens and to improve understanding of the causes, effects and treatment response of childhood nephrotic syndrome*

---

**Other**


---

<b>Cure GN</b>	<b>Cure Glomerulonephropathy Network</b>	Registry	<a href="#">Cai, Yi</a>	Emily Beltz <a href="mailto:Emily.Beltz@spectrumhealth.org">Emily.Beltz@spectrumhealth.org</a> (616) 486-4936
----------------	--	----------	-------------------------	---

The purpose of the CureGN is to create a source of information so that researchers can easily and effectively study rare glomerular disease such as MCD, FSGS, MN and IgAN, the underlying causes, identify markers of disease, and identify and evaluate new therapies.

<b>MWPNC GIGA</b>	<b>GIGA-kids Genomics of IgA related diseases in kids</b>	Treatment	<a href="#">Quiroga Chand, Alejandro</a>	Kathy Nystrom <a href="mailto:Kathy.Nystrom@spectrumhealth.org">Kathy.Nystrom@spectrumhealth.org</a> (616) 486-2062
-------------------	---	-----------	--	---

The purpose of this study will be to determine how some genes affect the development of IgAN and HSP by looking at biomarkers found in the blood. Normal, healthy children will also be enrolled in this study as matched controls and are required to perform adequate validations of biomarkers. IgA Nephropathy (IgAN) and Henoch-Schönlein Purpura (HSP) are related diseases, both thought to be due by deposits of the IgA antibody in the kidney. IgA nephropathy (IgAN) represents the leading cause of kidney failure among young adults, and the most frequent form of primary glomerulonephritis worldwide.

---

<b>Kaneka Liposorber LA-15 PAS</b>	<b>Treatment of Drug-resistant Pediatric Primary Focal Segmental Glomerulosclerosis Using the Liposorber® LA-15 System: Post Approval Study</b>	Observational	<a href="#">Quiroga Chand, Alejandro</a>	Emily Gleason <a href="mailto:Emily.Gleason@helendevoschildrens.org">Emily.Gleason@helendevoschildrens.org</a> (616) 486-6332
--	---	---------------	--	---

This is an observational research study for patients who have agreed to receive treatment with the Liposorber System. An observational study is a type of research in which individuals are observed over a period of time to measure outcomes, and no changes are made to the treatment participants receive. For this study we will collect information (or “data”) about your health and your treatment with the Liposorber system, and we will collect blood and urine samples at some visits for research lab tests. The information collected from study participants will be used to further evaluate the safety and probable benefit of this treatment.